Auditory Brainstem Implant Surgery in India — ABI for Profound Deafness
Auditory brainstem implant surgery in India from $25,000. ABI for patients without auditory nerves — NF2 and cochlear nerve aplasia. Specialist neurotology teams. Book with GAF Healthcare.
Estimated cost: $25,000 – $50,000 · Average stay: 7–14 days
An auditory brainstem implant (ABI) is an electronic hearing device that is surgically placed directly on the cochlear nucleus — the hearing centre of the brainstem — in patients who cannot benefit from a cochlear implant because their auditory (cochlear) nerves are absent, non-functional, or have been surgically removed. The ABI bypasses the entire auditory nerve pathway and stimulates the brainstem directly.
The most common indication for ABI is neurofibromatosis type 2 (NF2) — an autosomal dominant tumour suppressor gene mutation that causes bilateral vestibular schwannomas (acoustic neuromas), meningiomas, and ependymomas. The surgical removal of bilateral vestibular schwannomas inevitably sacrifices the cochlear nerves, leaving the patient profoundly deaf with no auditory nerve for a cochlear implant to stimulate. ABI is placed at the time of tumour removal surgery, simultaneously addressing the deafness.
ABI is also used for cochlear nerve aplasia (absent auditory nerve from birth — diagnosed on MRI), cochlear ossification (bony obliteration of the cochlea from meningitis, making cochlear implant impossible), and bilateral cochlear fractures from head trauma. It is a rare procedure — fewer than 2,000 ABIs have been implanted worldwide — performed at a handful of specialist neurotology centres. India's AIIMS New Delhi and Amrita Institute of Medical Sciences have neurotology and cochlear implant teams capable of performing ABI in selected patients.
ABI vs Cochlear Implant
A cochlear implant (CI) stimulates the auditory nerve by placing an electrode array inside the cochlea. It relies on an intact and functional cochlear nerve to transmit the electrical signals to the brain. ABI bypasses the cochlea and auditory nerve entirely, placing a flat pad electrode directly on the surface of the cochlear nucleus on the brainstem.
The sound perception outcomes of ABI are generally inferior to cochlear implant: most ABI users achieve awareness of environmental sounds, improved lip-reading ability, and understanding of simple patterns and rhythm — but only approximately 20–30% of adult ABI users achieve open-set speech understanding without lip-reading. Children with ABI implanted for cochlear nerve aplasia achieve somewhat better outcomes, particularly when implanted early, because the developing brain has greater neuroplasticity.
This outcome inferiority compared with cochlear implant reflects the fundamental anatomical difference: the cochlear nucleus receives inputs from thousands of hair cells organised in a precise tonotopic map; ABI stimulates only a portion of this nuclear surface with a limited number of electrodes, providing far less frequency discrimination than a cochlear implant with a full-length intracochlear electrode array.
Despite these limitations, ABI provides significant benefit to patients who have no alternative hearing option: it improves environmental sound awareness (alerting to doorbells, phones, alarms), enhances lip-reading performance, and for many patients meaningfully improves communication and quality of life. It is the only option that provides any hearing to patients without functional cochlear nerves.
ABI Surgical Procedure
ABI surgery is a major neurosurgical operation performed by a joint neurosurgeon and neurotologist team, taking 6–10 hours. The approach is usually through the posterior cranial fossa (suboccipital approach) — the same approach used for vestibular schwannoma removal in NF2.
The cochlear nucleus is identified on the lateral recess of the fourth ventricle (the brain cavity behind the brainstem). The ABI electrode paddle — a flat array of 12–21 electrode contacts mounted on a soft silicone pad — is carefully positioned on the surface of the cochlear nucleus complex, with the electrode contacts in direct contact with the brainstem surface. The internal receiver-stimulator unit is tunnelled subcutaneously and secured to the skull behind the ear.
Intraoperative neural response telemetry and electrically evoked auditory brainstem response (eABR) are used to confirm that the electrode is in the correct position before the wound is closed. The anaesthetic team must maintain appropriate depth of anaesthesia without neuromuscular blocking agents, because the surgical team relies on facial nerve and lower cranial nerve monitoring throughout.
After ABI implantation, the device is activated (switched on) 6–8 weeks after surgery to allow wound healing and resolution of post-operative swelling.
Procedure Steps
- Candidacy assessment: MRI cochlear nerve aplasia or NF2 confirmed; cochlear implant candidacy excluded
- Speech and language therapy baseline assessment; audiological evaluation
- General anaesthesia; intraoperative neural monitoring prepared
- Suboccipital craniotomy; tumour removal (if NF2); lateral recess of 4th ventricle identified
- ABI electrode paddle positioned on cochlear nucleus complex; eABR confirmation of placement
- Receiver-stimulator secured to skull; wound closure; ICU observation
- Device activation 6–8 weeks post-surgery; intensive auditory rehabilitation programme
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
USA — $150,000 – $250,000 — Save up to 85%
UK — £80,000 – £150,000 — Save up to 80%
UAE — Not routinely performed
India — $25,000 – $50,000 — Best value
ABI surgery in the USA or UK costs $150,000–$250,000 including the device, neurosurgery, neurotology, and extended hospital stay. In India, ABI implantation (device + surgery + hospital stay) costs $25,000–$50,000 at specialist neurotology centres. The ABI device itself (Cochlear Nucleus ABI) accounts for a significant portion of this cost; the surgical and hospital component is 60–70% cheaper than in the USA or UK.
Recovery & Follow-up
ABI surgery recovery is that of a major posterior fossa craniotomy: ICU observation for 24–48 hours; hospital discharge at 5–10 days; return to normal activities at 4–6 weeks. The ABI device is not activated until 6–8 weeks after surgery. After activation, extensive auditory therapy (learning to interpret ABI stimulation) continues for 12–24 months. Most users achieve maximum performance at 12–18 months after activation with consistent auditory rehabilitation.
Recovery Tips
- Attend all auditory rehabilitation sessions — the brain must learn to interpret ABI stimulation, and this learning is the primary determinant of the final outcome
- Use the ABI speech processor consistently throughout all waking hours to maximise auditory learning
- Combine ABI use with lip-reading training — the combination of ABI sound cues and visual lip-reading is significantly more effective than either alone
- Protect the implant site from trauma — avoid contact sports and activities with high head-impact risk
- Carry an ABI medical alert card — MRI is generally contraindicated after ABI implantation
Risks & Complications
ABI surgery risks include all the risks of posterior fossa craniotomy: cerebrospinal fluid leak; meningitis; haematoma; and facial nerve injury (the facial nerve is adjacent to the surgical field). Brainstem stimulation risks: non-auditory side effects from electrical stimulation of adjacent brainstem structures — tingling in the face, unsteadiness, or throat sensations — are common during initial programming and are managed by deactivating specific electrode contacts. Device failure requiring revision surgery is uncommon.
Why GAF Healthcare
GAF Healthcare coordinates ABI candidacy assessment and surgery with India's neurotology and cochlear implant specialists who have specific training in brainstem implantation. Pre-operative MRI review confirms candidacy before travel; the surgical team plans the combined tumour removal and ABI implantation procedure in detail before the patient arrives. Post-operative auditory rehabilitation can be partly coordinated remotely via our telemedicine programme.
Frequently Asked Questions
Who is eligible for an auditory brainstem implant?
ABI candidates are patients with profound bilateral deafness caused by absent, non-functional, or surgically removed cochlear nerves — where a cochlear implant cannot work. The most common candidates are: NF2 patients who have lost hearing from bilateral vestibular schwannoma surgery; children with bilateral cochlear nerve aplasia (absent auditory nerve from birth) confirmed on MRI; and patients with completely ossified cochleas from bilateral meningitis or trauma. All candidates require full audiological and neurotological evaluation before surgery.
Can children have an auditory brainstem implant?
Yes. ABI in children with cochlear nerve aplasia is increasingly performed at specialist centres globally. Children implanted early (age 2–5) achieve better outcomes than adults because of greater neuroplasticity. Some children with ABI develop open-set speech understanding — particularly those implanted very young. Results vary considerably between individuals. GAF Healthcare's partner centres have paediatric neurotology expertise for ABI in children.
How does ABI compare with cochlear implant in terms of hearing quality?
Cochlear implant outcomes are significantly better than ABI for most patients. The average cochlear implant user achieves open-set speech understanding (understanding words without lip-reading) of 70–90% in quiet conditions; the average adult ABI user achieves 20–30% open-set speech understanding. ABI users, however, report significant benefit in environmental sound awareness, lip-reading enhancement, and quality of life — and for patients without functional cochlear nerves, ABI is the only option available.